Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial
Toby Pepperrell, François Venter, Kaitlyn McCann, Bronwyn Bosch, Melissa Tibbatts, Joanna Woods, Simiso Sokhela, Celicia Serenata, Michelle Moorhouse, Ambar Qavi, Andrew Hill
Abstract
Following evidence of HIV RNA re-suppression on DTG-based regimens, we assess the re-suppressive capacity of ADVANCE participants on TAF/FTC+DTG, TDF/FTC+DTG, and TDF/FTC/EFV. Viraemic participants were able to re-suppress within 3 follow-up visits of protocol-defined virological failure (PDVF) in 77/121 (64%), 85/126 (67%), and 44/138 (32%) cases respectively (DTG regimens vs. TDF/FTC/EFV; P < 0.001).
Topics & Concepts
DolutegravirHuman immunodeficiency virus (HIV)MedicineInternal medicineVirologyOncologyViral loadAntiretroviral therapyHIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and Interventions